Foghorn Therapeutics (FHTX) Competitors

$4.04 -0.13 (-3.12%)

Closing price 04:00 PM Eastern

Extended Trading

$4.04 0.00 (-0.12%)

As of 04:04 PM Eastern

FHTX vs. DBVT, SEPN, SVRA, XERS, and ALVO

Should you buy Foghorn Therapeutics stock or one of its competitors? MarketBeat compares Foghorn Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Foghorn Therapeutics include DBV Technologies (DBVT), Septerna (SEPN), Savara (SVRA), Xeris Biopharma (XERS), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry.

How does Foghorn Therapeutics compare to DBV Technologies?

Foghorn Therapeutics (NASDAQ:FHTX) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Foghorn Therapeutics has a net margin of -266.88% compared to DBV Technologies' net margin of -2,895.37%. Foghorn Therapeutics' return on equity of 0.00% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-266.88%	N/A	-35.38%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

Foghorn Therapeutics currently has a consensus price target of $11.13, suggesting a potential upside of 175.37%. DBV Technologies has a consensus price target of $40.25, suggesting a potential upside of 102.87%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
DBV Technologies	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.67

61.6% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 7.6% of Foghorn Therapeutics shares are held by insiders. Comparatively, 1.4% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Foghorn Therapeutics has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	7.67	-$74.28M	-$1.16	N/A
DBV Technologies	N/A	N/A	-$146.95M	-$4.46	N/A

In the previous week, Foghorn Therapeutics had 5 more articles in the media than DBV Technologies. MarketBeat recorded 9 mentions for Foghorn Therapeutics and 4 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 0.47 beat Foghorn Therapeutics' score of 0.41 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Foghorn Therapeutics has a beta of 2.97, indicating that its stock price is 197% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.96, indicating that its stock price is 196% less volatile than the broader market.

Summary

Foghorn Therapeutics beats DBV Technologies on 13 of the 16 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Septerna?

Septerna (NASDAQ:SEPN) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Septerna has a net margin of -49.88% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

Septerna has higher revenue and earnings than Foghorn Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	27.78	-$48.88M	-$1.11	N/A
Foghorn Therapeutics	$30.91M	7.67	-$74.28M	-$1.16	N/A

61.6% of Foghorn Therapeutics shares are owned by institutional investors. 4.3% of Septerna shares are owned by company insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Foghorn Therapeutics had 2 more articles in the media than Septerna. MarketBeat recorded 9 mentions for Foghorn Therapeutics and 7 mentions for Septerna. Septerna's average media sentiment score of 0.48 beat Foghorn Therapeutics' score of 0.41 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Septerna presently has a consensus price target of $43.13, suggesting a potential upside of 52.28%. Foghorn Therapeutics has a consensus price target of $11.13, suggesting a potential upside of 175.37%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Septerna has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.97, indicating that its share price is 197% more volatile than the broader market.

Summary

Foghorn Therapeutics beats Septerna on 8 of the 15 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Savara?

Savara (NASDAQ:SVRA) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Savara has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.97, suggesting that its stock price is 197% more volatile than the broader market.

Savara currently has a consensus price target of $9.13, suggesting a potential upside of 73.15%. Foghorn Therapeutics has a consensus price target of $11.13, suggesting a potential upside of 175.37%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Savara has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-92.93%	-69.60%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

Foghorn Therapeutics has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Foghorn Therapeutics	$30.91M	7.67	-$74.28M	-$1.16	N/A

87.9% of Savara shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Foghorn Therapeutics had 3 more articles in the media than Savara. MarketBeat recorded 9 mentions for Foghorn Therapeutics and 6 mentions for Savara. Savara's average media sentiment score of 0.60 beat Foghorn Therapeutics' score of 0.41 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Foghorn Therapeutics beats Savara on 11 of the 15 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Xeris Biopharma?

Foghorn Therapeutics (NASDAQ:FHTX) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Foghorn Therapeutics has a beta of 2.97, suggesting that its share price is 197% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Foghorn Therapeutics presently has a consensus price target of $11.13, suggesting a potential upside of 175.37%. Xeris Biopharma has a consensus price target of $10.80, suggesting a potential upside of 69.28%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Foghorn Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Xeris Biopharma has a net margin of 3.81% compared to Foghorn Therapeutics' net margin of -266.88%. Xeris Biopharma's return on equity of 735.00% beat Foghorn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-266.88%	N/A	-35.38%
Xeris Biopharma	3.81%	735.00%	3.24%

Xeris Biopharma has higher revenue and earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	7.67	-$74.28M	-$1.16	N/A
Xeris Biopharma	$314.85M	3.50	$550K	$0.06	106.33

61.6% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 7.6% of Foghorn Therapeutics shares are held by insiders. Comparatively, 6.5% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Xeris Biopharma had 5 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 14 mentions for Xeris Biopharma and 9 mentions for Foghorn Therapeutics. Xeris Biopharma's average media sentiment score of 0.58 beat Foghorn Therapeutics' score of 0.41 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xeris Biopharma	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xeris Biopharma beats Foghorn Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Foghorn Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVO) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Alvotech has a net margin of -14.36% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Alvotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.58%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

Alvotech presently has a consensus price target of $7.60, suggesting a potential upside of 121.57%. Foghorn Therapeutics has a consensus price target of $11.13, suggesting a potential upside of 175.37%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

61.6% of Foghorn Therapeutics shares are owned by institutional investors. 0.5% of Alvotech shares are owned by company insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alvotech has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.97, suggesting that its share price is 197% more volatile than the broader market.

Alvotech has higher revenue and earnings than Foghorn Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	1.76	$27.92M	-$0.25	N/A
Foghorn Therapeutics	$30.91M	7.67	-$74.28M	-$1.16	N/A

In the previous week, Alvotech and Alvotech both had 9 articles in the media. Foghorn Therapeutics' average media sentiment score of 0.41 beat Alvotech's score of 0.27 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Foghorn Therapeutics beats Alvotech on 11 of the 16 factors compared between the two stocks.

Get Foghorn Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FHTX vs. The Competition

Export

Metric	Foghorn Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$237.19M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-3.48	18.98	20.89	25.59
Price / Sales	7.67	176.16	522.17	62.83
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	-3.11	6.74	9.86	6.70
Net Income	-$74.28M	$24.11M	$3.55B	$333.77M
7 Day Performance	-3.81%	0.06%	-0.32%	0.45%
1 Month Performance	-16.70%	0.81%	1.33%	4.06%
1 Year Performance	-1.70%	78.08%	41.10%	36.24%

Foghorn Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FHTX Foghorn Therapeutics	2.8813 of 5 stars	$4.04 -3.1%	$11.13 +175.4%	-3.7%	$244.84M	$28.22M	N/A	120	Earnings Report Analyst Revision
DBVT DBV Technologies	2.9271 of 5 stars	$19.49 +0.1%	$40.25 +106.5%	+78.3%	$1.09B	N/A	N/A	80
SEPN Septerna	3.4143 of 5 stars	$24.13 -2.8%	$43.13 +78.7%	+267.8%	$1.08B	$45.95M	N/A	N/A	News Coverage Earnings Report Upcoming Earnings Analyst Forecast
SVRA Savara	2.5288 of 5 stars	$5.25 -0.9%	$9.13 +73.8%	+77.4%	$1.08B	N/A	N/A	20	Earnings Report
XERS Xeris Biopharma	3.0163 of 5 stars	$6.23 -1.7%	$10.80 +73.4%	+31.2%	$1.08B	$291.85M	N/A	290	Earnings Report Analyst Downgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FHTX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Foghorn Therapeutics (FHTX) Competitors

FHTX vs. DBVT, SEPN, SVRA, XERS, and ALVO

How does Foghorn Therapeutics compare to DBV Technologies?

Summary

How does Foghorn Therapeutics compare to Septerna?

Summary

How does Foghorn Therapeutics compare to Savara?

Summary

How does Foghorn Therapeutics compare to Xeris Biopharma?

Summary

How does Foghorn Therapeutics compare to Alvotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX vs. The Competition

Foghorn Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Foghorn Therapeutics (FHTX) Competitors

FHTX vs. DBVT, SEPN, SVRA, XERS, and ALVO

How does Foghorn Therapeutics compare to DBV Technologies?

Is FHTX or DBVT more profitable?

Do analysts rate FHTX or DBVT?

Do institutionals & insiders have more ownership in FHTX or DBVT?

Which has better earnings and valuation, FHTX or DBVT?

Does the media favor FHTX or DBVT?

Which has more volatility & risk, FHTX or DBVT?

Summary

How does Foghorn Therapeutics compare to Septerna?

Is SEPN or FHTX more profitable?

Which has higher valuation & earnings, SEPN or FHTX?

Do institutionals and insiders have more ownership in SEPN or FHTX?

Does the media refer more to SEPN or FHTX?

Do analysts prefer SEPN or FHTX?

Which has more risk & volatility, SEPN or FHTX?

Summary

How does Foghorn Therapeutics compare to Savara?

Which has more volatility and risk, SVRA or FHTX?

Do analysts rate SVRA or FHTX?

Is SVRA or FHTX more profitable?

Which has higher valuation and earnings, SVRA or FHTX?

Do insiders & institutionals hold more shares of SVRA or FHTX?

Does the media refer more to SVRA or FHTX?

Summary

How does Foghorn Therapeutics compare to Xeris Biopharma?

Which has more volatility & risk, FHTX or XERS?

Do analysts rate FHTX or XERS?

Is FHTX or XERS more profitable?

Which has stronger valuation & earnings, FHTX or XERS?

Do institutionals & insiders hold more shares of FHTX or XERS?

Does the media prefer FHTX or XERS?

Summary

How does Foghorn Therapeutics compare to Alvotech?

Is ALVO or FHTX more profitable?

Do analysts prefer ALVO or FHTX?

Do insiders and institutionals hold more shares of ALVO or FHTX?

Which has more risk and volatility, ALVO or FHTX?

Which has preferable earnings and valuation, ALVO or FHTX?

Does the media favor ALVO or FHTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FHTX vs. The Competition

Foghorn Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools